Official instruction for use
LSR № 006779
Trade name of the preparation:
INN or grouping name:
Composition (per one capsule)
Active ingredient: aminophenylbutyric acid hydrochloride is 25 mg or 50 mg or 125 mg or 250 mg.
Excipients: giprolose, silicon dioxide colloid, lactose, magnesium stearate.
Hard gelatin capsules contain: for dosage of 25 mg - water, gelatin, methyl parahydroxybenzoate, propyl parahydroxybenzoate, titanium dioxide (E 171); For dosage of 50 mg - water, gelatin, dye azorubin (E 122), brilliant blue (E 133), quinoline yellow (E 104), methyl parahydroxybenzoate, propyl parahydroxybenzoate, titanium dioxide (E 171); For the dosage of 125 mg - water, gelatin, dye azorubin (E 122), brilliant blue (E 133), methyl parahydroxybenzoate, propyl parahydroxybenzoate, titanium dioxide (E 171); For dosage of 250 mg - water, gelatin, dye azorubin (E 122), brilliant blue (E 133), methyl parahydroxybenzoate, propyl parahydroxybenzoate, titanium dioxide (E 171).
Dosage of 25 mg - capsules No 3 white.
Dosage 50 mg - capsules No 3, body white, cover blue.
Dosage of 125 mg - capsules No 2, white body, lid of blue color.
Dosage 250 mg - capsules No 0, body white, cover dark blue.
Contents of capsules - a mixture of powder and / or granules of white or white with a yellowish hue.
Nootropic agent, facilitates GABA-mediated transmission of nerve impulses in the central nervous system (direct effect on GABAergergic receptors). The tranquilizing effect is combined with the activating effect. It also has antiplatelet, antioxidant and some anticonvulsant action.
Improves the functional state of the brain due to the normalization of its metabolism and influence on the cerebral blood flow (increases volumetric and linear speed, reduces vascular resistance, improves microcirculation, has antiaggregant effect). It prolongs the latent period and shortens the duration and severity of nystagmus.
Does not affect cholino- and adrenergic receptors. Reduces vasovegetative symptoms (including headache, sensation of heaviness in the head, sleep disorders, irritability, emotional lability). At the course reception increases physical and mental efficiency (attention, memory, speed and accuracy of sensory-motor reactions).
Reduces the manifestations of asthenia (improves well-being, increases interest and initiative (motivation of activity)) without sedation or arousal. Helps reduce feelings of anxiety, tension and anxiety, normalizes sleep.
In people of advanced age do not cause central nervous system depression, muscle-relaxing aftereffect is most often absent.
Absorption is high, it penetrates well into all tissues of the body and across the blood-brain barrier (about 0.1% of the injected dose penetrates the brain tissue, and to a much greater extent in young and elderly people). Evenly distributed in the liver and kidneys. Metabolized in the liver - 80-95%, metabolites are not pharmacologically active. Does not cumulate. After 3 hours begins to be excreted by the kidneys, while the concentration in the brain tissue does not decrease and is detected for another 6 hours. About 5% is excreted by the kidneys unchanged, partly with bile.
Indications for use
Asthenic and anxiety-neurotic states.
Stammering, tics and enuresis in children.
Insomnia and nightly anxiety in the elderly.
Ménière's disease, dizziness associated with dysfunction of the vestibular analyzer of various genesis; Prevention of motion sickness with kinetosis.
As part of the complex therapy of alcohol withdrawal syndrome for the relief of psychopathological and somatovegetative disorders.
Hypersensitivity, pregnancy, breastfeeding, children under 3 years.
With erosive and ulcerative lesions of the gastrointestinal tract, hepatic insufficiency.
Dosing and Administration
Inside after eating 2-3-week courses. Adults and children from 14 years to 250-500 mg 3 times a day (maximum daily dose of 2500 mg). Children from 3 to 8 years of 50-100 mg 3 times a day; From 8 to 14 years - 250 mg 3 times a day.
A single maximum dose in adults and children from the age of 14 is 750 mg, in people over 60 years - 500 mg, in children under 8 years - 150 mg, from 8 to 14 years - 250 mg.
250-500 mg 3 times a day and 750 mg at night, with a gradual decrease in the daily dose to normal for adults.
Treatment of dizziness with dysfunction of the vestibular apparatus and Meniere's disease: 250 mg 3 times a day for 14 days.
Prevention of motion sickness: 250-500 mg once for 1 hour before the expected start of the pitching or when the first symptoms of seasickness appear. The anti-foaming effect of Anvifen is enhanced by increasing the dose of the drug. At the onset of severe manifestations of seasickness (vomiting, etc.), the appointment of Anvifen is ineffective even in doses of 750-1000 mg.
Drowsiness, nausea. Enhancement of irritability, agitation, anxiety, dizziness, headache (at the first receptions), allergic reactions.
Symptoms: severe drowsiness, nausea, vomiting, fatty degeneration of the liver (taking more than 7 g), eosinophilia, lowering blood pressure, impaired renal function. Treatment: gastric lavage, reception of activated charcoal and symptomatic therapy. Interaction with other medicinal products Extends and intensifies the effect of hypnotics, narcotic analgesics, neuroleptics, antiparkinsonian and antiepileptic drugs.
With prolonged use, it is necessary to periodically monitor the performance of the liver and peripheral blood. It is necessary to refrain from potentially dangerous activities that require increased concentration.
Form of issue
Capsules 25 mg, 50 mg, 125 mg, 250 mg.
For 10 capsules of a single dosage in a contour squamous packaging.
1, 2, 3 or 5 contour mesh packages together with instructions for use in a pack of cardboard.
List B. In a dry, the dark place at a temperature of no higher than 25 оС. Keep out of the reach of children.
3 years. Do not use after the expiry date printed on the package.
Terms of leave from pharmacies